spec sheet12 rows
Hydergine is the trade name for ergoloid mesylates, a mixture of methanesulfonate salts of several hydrogenated ergot alkaloids derived from the ergot fungus. Developed by Albert Hofmann at Sandoz, it was long prescribed for age-related cognitive decline and cerebral insufficiency and is often cited as one of the earliest nootropics. Reviews of its use in dementia have found modest overall effects and good tolerability, though its efficacy remains uncertain.
- Mild cognitive support in older adults
- Possible cerebral blood flow support
- Long track record of clinical use
- Generally mild side effect profile
- one of the original 'smart drugs' (Hofmann/Sandoz, 1940s) with decades of clinical use
- Cochrane-level evidence of modest benefit on global and comprehensive dementia ratings (OR ~3.78 on global rating)
- broad multi-system ergoline action: alpha-adrenergic, dopaminergic, serotonergic, metabolic, antioxidant
- Nausea
- Gastrointestinal upset
- Nasal congestion
- Lightheadedness
- Rare ergot-related effects with long-term use
Overview
Hydergine is a brand name for ergoloid mesylates, also known as dihydroergotoxine or co-dergocrine, a combination drug made from the methanesulfonate salts of three dihydrogenated ergot alkaloids: dihydroergocristine, dihydroergocornine, and dihydroergocryptine [1]. These alkaloids are derived from ergot, a fungus that grows on grain and carries a long and colorful history in pharmacology [1]. The hydrogenation of the parent alkaloids reduces their potent blood-vessel-constricting effects and yields a compound better suited to long-term use [1].
The drug was developed by the Swiss chemist Albert Hofmann, better known for first synthesizing LSD, while working at Sandoz, the company that later became part of Novartis [1]. Introduced in the mid-twentieth century, Hydergine became widely prescribed for older adults, and it is frequently described as one of the original nootropic or cognition-enhancing agents that predated the modern supplement category [4].
Its principal medical use has been in the treatment of age-related decline in mental function, a loosely defined indication historically labeled cerebral insufficiency, and it has been applied to dementia, including Alzheimer's disease and vascular dementia, as well as to symptoms following stroke [2][4]. Because of its ergot origins and dopamine activity, it was also used at times to lower elevated prolactin levels [1]. In practice its use has declined as newer treatments emerged and diagnostic standards for dementia became more precise [3].
The evidence for Hydergine's effectiveness is mixed and much debated. A 1994 systematic review found that it was more effective than placebo overall, yet noted that the effect in patients with probable Alzheimer's disease was very modest [2]. A subsequent Cochrane review similarly reported statistically significant benefits on global and comprehensive rating scales along with good tolerability, while cautioning that many of the trials predated modern diagnostic criteria and that uncertainty about its true efficacy persists [3]. Research has suggested that any benefit is more likely tied to effects on neurotransmission than to a simple increase in blood flow, as was once assumed [4].
Ergoloid mesylates are a prescription medicine, and the drug is generally well tolerated, with side effects that are usually mild and transient, most commonly nausea and gastrointestinal upset [2]. As with other ergot derivatives, concerns about rare adverse effects such as fibrosis and features of ergotism contributed to regulatory restrictions on ergoline drugs for circulatory and memory indications in some European countries [1]. Hydergine has been supplied as oral tablets, sublingual tablets, and liquid formulations.
- hydergine was created in albert hofmann's lab at sandoz, the same chemist who first synthesised lsd; both come from the ergot alkaloid family.
- it is widely regarded as the original 'smart drug', in clinical use for age-related mental decline since the 1940s.
- 'hydergine', 'ergoloid mesylates', 'dihydroergotoxine' and 'co-dergocrine' are all the same drug, a mixture of four dihydro-ergot alkaloids.
Mechanism
hydergine is co-dergocrine, also called ergoloid mesylates or dihydroergotoxine: a defined mixture of hydrogenated ergot alkaloids (dihydroergocornine, dihydroergocristine and the alpha and beta dihydroergocryptine isomers, as mesylate salts) first synthesised in albert hofmann's lab at sandoz in the 1940s. because it is a mixture of promiscuous ergolines, its pharmacology is deliberately broad rather than targeted. it antagonises alpha-1 and alpha-2 adrenoceptors, which dilates cerebral vessels and raises blood flow; it acts as a partial at and receptors and modulates 5-HT2 receptors, contributing to its mood and vascular effects; and it is long claimed to improve neuronal metabolism (glucose and oxygen utilisation), stabilise second-messenger () signalling, and reduce . no single one of these is dramatic; the drug's clinical effect is the sum of many small nudges on the ageing brain. the human evidence, pooled in the cochrane review by olin et al across 19 double-blind placebo-controlled trials, shows a modest but statistically real benefit on global clinical ratings (odds ratio 3.78) and comprehensive rating scales (doi 10.1002/14651858.CD000359), a finding echoed in later psychiatric reviews of cognitive enhancers (doi 10.1192/bjp.188.2.109). the reviewers are candid that most trials predate the 1984 consensus dementia criteria, so the treated populations are heterogeneous and the effect sizes small. head-to-head, it performs about the same as nicergoline (ladurner et al 1991, pmid 2014712). the practical framing is that hydergine is a legacy, gently effective, cheap ergoline mixture, historically important as the first widely used 'smart drug', now largely displaced by cholinesterase inhibitors and constrained by the ergot-class fibrosis risk that led to the 2013 european restrictions on ergot derivatives.
receptor fingerprint
Alpha-1 adrenoceptorantagonist
Alpha-2 adrenoceptorantagonist / partial agonist
receptorpartial agonist
5-HT2 receptorsantagonist / partial agonist
receptorpartial agonist
Neuronal metabolism (glucose/O2 utilisation)enhances
/ phosphodiesterase signallingmodulates
/ free radicalsreduces (antioxidant)
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Generally well tolerated at standard doses, with nausea, headache, dizziness, and GI upset being the usual complaints. As an ergot derivative it can theoretically cause vasoconstriction concerns, so people with certain circulatory or heart conditions should be careful. It can interact with other ergot drugs and some dopaminergic medications.
Subjective profileweighing the evidence above
An interesting piece of nootropic history, but there are cleaner tools now; not worth building a stack around.
Resources
This entry is here for reference.
Research
- 1991first cited[Therapy of organic brain syndrome with nicergoline given once a day].
- 2006most recentErgot and its alkaloids
- 1.Ergot and its alkaloids
- 2.Overview of clinical trials of hydergine in dementia
- 3.Hydergine for dementia.
- 4.Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives
- 5.Complementary medicines in psychiatry: review of effectiveness and safety
- 6.Pleuropulmonary changes induced by ergoline drugs.
- 7.[Therapy of organic brain syndrome with nicergoline given once a day].
7 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
is hydergine a smart drug?
it's one of the original 'smart drugs', predating the modern nootropics scene by decades. it's co-dergocrine (ergoloid mesylates): a mixture of hydrogenated ergot alkaloids first developed in the 1940s (albert hofmann's lab at sandoz, the same chemist behind lsd). it was prescribed for years for age-related mental decline. it has real, if modest and dated, placebo-controlled evidence; it's not a stimulant and won't give you a noticeable lift.
does it actually work?
modestly, per the best available synthesis. the cochrane review by olin et al pooled 19 double-blind placebo-controlled trials and found hydergine beat placebo on global ratings (odds ratio 3.78) and comprehensive rating scales (doi 10.1002/14651858.CD000359). the honest caveat the reviewers themselves raise: most trials predate the 1984 consensus dementia criteria, so who was actually being treated is fuzzy, and effect sizes are small. a later psychiatry review still listed hydergine among the few complementary cognitive enhancers with supporting evidence (doi 10.1192/bjp.188.2.109).
what's it actually made of?
it's a defined mixture, not a single molecule: roughly equal parts dihydroergocornine, dihydroergocristine and the alpha + beta isomers of dihydroergocryptine, as the mesylate salts. that's why it goes by so many names (ergoloid mesylates, dihydroergotoxine, co-dergocrine). the mixture is the thing that was studied, which matters because the individual components on their own don't carry the same evidence.
how does it work?
it's a broad ergoline, so it touches several systems at once rather than one clean target. it antagonises alpha-adrenoceptors (raising cerebral blood flow), acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and is claimed to improve neuronal metabolism (glucose and oxygen use) and reduce oxidative stress. the metabolic and neuroprotective story is the classic explanation for its use in the 'ageing brain', but none of the single mechanisms is dramatic; the effect is the sum of small nudges.
does it work right away?
no. like the other vasoactive ergots, any benefit builds over weeks to months of daily dosing, not hours. it was dosed chronically (commonly 3-4.5 mg/day, sometimes up to 6 mg) for months in the trials. if you're expecting an acute cognitive kick you'll be disappointed; this is a slow, subtle agent.
is it safe long term?
at the low doses used it was generally well tolerated in trials (about 78% completion), with mild issues like nausea, stomach upset, headache, flushing and low blood pressure. the real long-horizon concern is the ergot-class one: chronic ergoline use is linked to fibrosis (pleura/lung, heart valves, retroperitoneum). related ergolines including nicergoline and dihydroergocristine have caused pleuropulmonary changes (doi 10.1183/09031936.96.09051013), and in 2013 the ema restricted ergot derivatives partly for this reason. low-dose, time-limited use is the sane approach.
can i take it with racetams?
people historically stacked hydergine with piracetam, the idea being cholinergic/metabolic support alongside a racetam. it's a plausible pairing and was popular in the old nootropics community, but the evidence for the combo specifically is anecdotal, not trial-backed. if you do it, keep doses modest and remember hydergine can lower blood pressure.
is it still prescribed?
much less than it used to be. it was largely superseded for dementia by cholinesterase inhibitors and memantine, and the 2013 ema ergot restrictions pushed it further to the margins in europe. it still exists and is cheap, but it's a legacy agent now, more of interest for its history (hofmann, the first 'smart drug') than as a current first-line treatment.
how is it different from nicergoline?
they're close cousins from the same ergoline shelf and perform similarly in head-to-head trials (20 mg nicergoline once daily matched 4.5 mg co-dergocrine, pmid 2014712). hydergine is a mixture leaning on partial dopamine/serotonin agonism and metabolic effects; nicergoline is a single molecule whose dominant action is potent alpha-1 blockade plus a stronger cholinergic/neurotrophic push. neither is dramatic; nicergoline arguably has the slightly richer mechanistic story.
Adverse effects
- Nausea
- Gastrointestinal upset
- Nasal congestion
- Lightheadedness
- Rare ergot-related effects with long-term use